Literature DB >> 1528709

Handling of risk-bearing drugs during pregnancy. Do we choose less risky alternatives?

L T De Jong-Van den Berg1, P B Van den Berg, F M Haaijer-Ruskamp, M N Dukes, H Wesseling.   

Abstract

The drug use of nearly 2,000 pregnant women was evaluated at the level of the individual patient for the drugs belonging to the Australian risk categories B3, C and D. The pattern of changes in the use of these drugs is studied in terms of women who discontinue (d), continue (c) or begin (b) using the drug during pregnancy. The ratios d/(c+b) and d/b were the highest for the drugs belonging to the high-risk groups and the lowest for drugs from the low-risk categories. This suggests a congruence between theoretical knowledge and daily practice. Patients who had already been using a drug for a long time before pregnancy, more frequently continued using that drug than patients who had been using the drug only incidentally before. The described daily dose for the riskful drugs was approximately 20% lower in patients who started to use a drug during pregnancy compared to those who continued drug use. The data from this analysis indicate that the prescribing physician is generally aware of the possible risks of drug use during pregnancy. The d/(b+c) and d/b ratios are shown to be a good measure of prescribing behaviour in relation to pregnancy and can be used to compare knowledge of theory and daily practice.

Entities:  

Mesh:

Year:  1992        PMID: 1528709     DOI: 10.1007/bf01980480

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  14 in total

1.  Drug use in pregnancy: a preliminary report of the International co-operative Drug Utilization Study. Collaborative Group on Drug Use in Pregnancy.

Authors: 
Journal:  Pharm Weekbl Sci       Date:  1990-04-27

2.  Drug prescribing during pregnancy. A controlled study of Tennessee Medicaid recipients.

Authors:  J C Brocklebank; W A Ray; C F Federspiel; W Schaffner
Journal:  Am J Obstet Gynecol       Date:  1978-10-01       Impact factor: 8.661

3.  Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women.

Authors:  A L Herbst; H Ulfelder; D C Poskanzer
Journal:  N Engl J Med       Date:  1971-04-15       Impact factor: 91.245

4.  Isotretinoin dose and teratogenicity.

Authors:  F Rosa
Journal:  Lancet       Date:  1987-11-14       Impact factor: 79.321

5.  Abnormalities in children exposed to benzodiazepines in utero.

Authors:  L Laegreid; R Olegård; J Wahlström; N Conradi
Journal:  Lancet       Date:  1987-01-10       Impact factor: 79.321

Review 6.  Antirheumatic medication in pregnancy.

Authors:  C J Needs; P M Brooks
Journal:  Br J Rheumatol       Date:  1985-08

7.  Obtaining drug exposure histories during pregnancy.

Authors:  T W Bodendorfer; G G Briggs; J E Gunning
Journal:  Am J Obstet Gynecol       Date:  1979-10-15       Impact factor: 8.661

8.  Prescription drug use before and during pregnancy in a Medicaid population.

Authors:  J M Piper; C Baum; D L Kennedy
Journal:  Am J Obstet Gynecol       Date:  1987-07       Impact factor: 8.661

9.  A study of drug utilization in pregnancy in the light of known risks: is there room for improvement?

Authors:  L T de Jong-van den Berg; P B van den Berg; P W Peters; F M Haaijer-Ruskamp
Journal:  Int J Risk Saf Med       Date:  1990

10.  Low-dose aspirin in pregnancy.

Authors:  B M Sibai; R Mirro; C M Chesney; C Leffler
Journal:  Obstet Gynecol       Date:  1989-10       Impact factor: 7.661

View more
  1 in total

Review 1.  Effect of over-the-counter drugs on the unborn child: what is known and how should this influence prescribing?

Authors:  S Kacew
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.